- Home
- MCRB vs LFVN Comparison
MCRB vs LFVN Comparison
Compare MCRB & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- LFVN
- Stock Information
- Founded
- MCRB 2010
- LFVN N/A
- Country
- MCRB United States
- LFVN United States
- Employees
- MCRB N/A
- LFVN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- LFVN Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- LFVN Health Care
- Exchange
- MCRB Nasdaq
- LFVN Nasdaq
- Market Cap
- MCRB 144.6M
- LFVN 145.2M
- IPO Year
- MCRB 2015
- LFVN N/A
- Fundamental
- Price
- MCRB $17.75
- LFVN $8.85
- Analyst Decision
- MCRB Hold
- LFVN Strong Buy
- Analyst Count
- MCRB 4
- LFVN 2
- Target Price
- MCRB $14.33
- LFVN $30.50
- AVG Volume (30 Days)
- MCRB 101.5K
- LFVN 128.6K
- Earning Date
- MCRB 11-12-2025
- LFVN 11-04-2025
- Dividend Yield
- MCRB N/A
- LFVN 2.05%
- EPS Growth
- MCRB N/A
- LFVN 226.09
- EPS
- MCRB 10.22
- LFVN 0.75
- Revenue
- MCRB N/A
- LFVN $228,530,000.00
- Revenue This Year
- MCRB N/A
- LFVN $6.93
- Revenue Next Year
- MCRB N/A
- LFVN $1.43
- P/E Ratio
- MCRB $1.74
- LFVN $11.69
- Revenue Growth
- MCRB N/A
- LFVN 14.17
- 52 Week Low
- MCRB $6.53
- LFVN $8.50
- 52 Week High
- MCRB $24.67
- LFVN $27.38
- Technical
- Relative Strength Index (RSI)
- MCRB 42.40
- LFVN 33.06
- Support Level
- MCRB $17.63
- LFVN $8.50
- Resistance Level
- MCRB $19.30
- LFVN $9.33
- Average True Range (ATR)
- MCRB 1.12
- LFVN 0.36
- MACD
- MCRB -0.29
- LFVN 0.06
- Stochastic Oscillator
- MCRB 5.42
- LFVN 33.04
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.